Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial.
about
Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarctionAdenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotectionIschaemic postconditioning: cardiac protection after the eventPostconditioning signalling in the heart: mechanisms and translatabilityCardioprotection: Where to from here?ATL 313, A Selective A(2A) Adenosine Receptor Agonist, Reduces Myocardial Infarct Size in a Rat Ischemia/Reperfusion ModelAdenosine A1 receptor activation increases myocardial protein S-nitrosothiols and elicits protection from ischemia-reperfusion injury in male and female heartsNovel adjunctive treatments of myocardial infarction.Extracellular nucleotide and nucleoside signaling in vascular and blood diseaseThe REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised cIntracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective studyRecent advances in the diagnosis and treatment of acute myocardial infarctionComparison of the effects of adenosine, inosine, and their combination as an adjunct to reperfusion in the treatment of acute myocardial infarctionOn-pump inhibition of es-ENT1 nucleoside transporter and adenosine deaminase during aortic crossclamping entraps intracellular adenosine and protects against reperfusion injury: role of adenosine A1 receptor.Protection of the ischemic myocardium during the reperfusion: between hope and reality.Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance.Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning.Potential economic consequences of a cardioprotective agent for patients with myocardial infarction: modelling study.Reperfusion injury: does it exist?Percutaneous coronary intervention and the no-reflow phenomenon.Pharmacologic therapeutics for cardiac reperfusion injury.New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute WorkshopStrategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial.Management of 'no-reflow' complicating reperfusion therapy.Cardioprotection and myocardial reperfusion: pitfalls to clinical applicationCardioprotective effects of adenosine within the border and remote areas of myocardial infarctionAdenosine receptors and reperfusion injury of the heartPerioperative organ injury.Cardiac stunning in the clinic: the full picture.Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonistTargeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations.Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.Myocardial protection in heart surgery.Remote ischemic conditioning: a clinical trial's update.Clinical efforts to reduce myocardial infarct size--the next step.Targeting adenosine receptors in the development of cardiovascular therapeutics.The future: therapy of myocardial protection.Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy.Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
P2860
Q24187926-ACCA3EB8-9900-4ED5-938D-BFC494CF1B1AQ24202298-8763386C-280D-4787-A77C-05BD6474ABC2Q26750797-4C894686-1490-415C-A3D6-E6C875A809B6Q26853129-B4E43D61-5457-4C1E-8158-B37334AD932DQ27021021-55CEF613-CB50-41F5-9D88-69B33189068BQ30244797-14EEF97A-F994-46EE-9C75-C1AFF3858F0FQ33612497-A690D34C-34A8-467A-B746-02D01F677F3CQ33663800-3B316CF3-8E04-4FEA-91B0-DF97F3467785Q33812924-82FDD802-005B-486F-B4CD-DDB23B16B367Q34047834-3EC2148A-9643-48B0-ACCA-25BB34A70E13Q34305843-9744D60E-8807-4A2B-B89A-AEDDD8B46099Q35158641-0B13750E-0651-4C76-A76B-42D34F16BCDFQ35626702-C43CE3C3-5341-480F-80BF-90D01A4A8533Q35853403-2A78C6C3-7F1F-4838-BA48-D0B377A54BEEQ35968771-CD722BA7-3500-416A-90CB-46DF26DAA196Q36190291-0FD52959-BB33-42DF-931D-3106D8CCD294Q36288870-1FE9D27D-18FA-4DE1-8300-5E7440A16802Q36288965-DCF6F723-3289-441E-BA23-A4FC941E7744Q36302787-E4A878CF-F51F-49AA-B39A-3D19E1766E7FQ36636752-36B2FB8B-387C-471A-8EC0-3B617542F8F4Q36867295-9028001F-29BB-49F2-9C73-89775969FE0AQ36944008-770D85FC-DC19-463B-97B7-F188F53D5C4FQ37007953-753819C1-D9E4-47E6-AD14-F51E74FB21EAQ37030536-F2B8A716-9987-469C-915F-76F8BA3CEF6DQ37152013-75ECCA8F-1236-4208-B24D-AC152CC15625Q37298516-0582FC51-84D8-4932-B625-75B87CDD3042Q37356878-B1EE4632-8608-40DD-8404-97D5B7E5C00BQ37565166-1F207A32-A593-496D-BA95-C8649A9B6038Q37593569-20B5C681-4B69-4827-B97E-170B9E138144Q37601769-0945C247-22A3-488C-88C6-1B2E5BEF9010Q37674601-A048637D-79FC-4553-877C-D00D3564DBFCQ37738596-E6948041-5069-47D7-A3B9-AEA39C8312DBQ37744271-8211A29A-D5CE-4762-B421-EA045A043670Q37912849-4D119975-D9C1-4956-8532-A09764F700CBQ37912853-5710C2E9-60FA-4C48-9BC4-72FEF6DCDE9DQ37912861-891E0EF6-2600-4E66-AF71-D610ACD52005Q37990558-CD2C2835-64B2-479B-B4DC-A00D5AECD0CFQ38006737-CBA7C374-C58C-4417-AE43-B56E7827F7DCQ38010782-DBE5614E-DC8A-4D9D-B746-598A2F5961BAQ38040816-286E73D3-C8C9-4D53-82FA-51E8213AA7E0
P2860
Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Impact of time to therapy and ...... farction: the AMISTAD-2 trial.
@en
Impact of time to therapy and ...... farction: the AMISTAD-2 trial.
@nl
type
label
Impact of time to therapy and ...... farction: the AMISTAD-2 trial.
@en
Impact of time to therapy and ...... farction: the AMISTAD-2 trial.
@nl
prefLabel
Impact of time to therapy and ...... farction: the AMISTAD-2 trial.
@en
Impact of time to therapy and ...... farction: the AMISTAD-2 trial.
@nl
P2093
P356
P1476
Impact of time to therapy and ...... farction: the AMISTAD-2 trial.
@en
P2093
Allan M Ross
Gregg W Stone
Mervyn B Forman
R Wayne Alexander
Raymond J Gibbons
Robert A Kloner
P304
P356
10.1093/EURHEARTJ/EHL094
P577
2006-06-16T00:00:00Z